- WHY CARE ABOUT MYANMAR?
- WHO WE ARE
"The costs of widespread artemisinin resistance in terms of lives lost and resources used, in Asia and Africa, would be immense," write Frank Smithuis, director of Medical Action Myanmar, and Nick White, professor of tropical medicine at the Mahidol Oxford Tropical Medicine Research Unit in Bangkok, in a March 29, 2012 New York Times op-ed. "Myanmar is the next frontier in the spread of artemisinin resistance, and the likely conduit for its spread west . . .The world cannot afford to lose this battle."